Getinge (GETI.B) AI Stock Analysis

• Market Cap: kr53.22B
• Dividend Yield: 2.16%
• Average Volume (3M): 472.77K
• Price to Earnings (P/E): 23.6
• Beta (1Y): 0.81
• Revenue Growth: 6.74%
• EPS Growth: 21.40%
• Country: SE
• Employees: 11,827
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 4.45
• Shares Outstanding: 254,152,370
• 10 Day Avg. Volume: 671,507
• 30 Day Avg. Volume: 472,771
• PEG Ratio: 0.70
• Price to Book (P/B): 2.03
• Price to Sales (P/S): 1.70
• P/FCF Ratio: 22.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr235.00
• Price Target Upside: 8.34% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: kr203.00 ▼(-6.41% Downside)

The score is held back mainly by weak technical momentum (trading below key moving averages with negative MACD). Financials are stable but not strong, reflecting flat growth and uneven profitability/cash flow, while valuation is mixed with a moderate dividend partially offsetting a mid-to-high P/E.

Positive Factors

Recurring revenue & service contracts

Getinge's mix of direct product sales plus ongoing maintenance, service contracts and consumables builds recurring revenue. That recurring income increases customer stickiness, stabilizes cash flows and supports durable margin and investment planning over the next 2–6 months.

Broad, diversified product portfolio

Exposure across Surgical Workflows, Critical Care and Life Science provides structural diversification and cross‑sell opportunities. Serving hospitals and biopharma reduces single‑market cyclicality and lets R&D investments leverage multiple end markets for sustained revenue resilience.

Positive operating cash generation

Consistent operating cash flow and historically strong free cash flow (notably 2024) give Getinge the ability to fund R&D, service debt and support capex or dividends. Solid cash generation underpins financial flexibility through typical industry cycles.

Negative Factors

Flat and uneven revenue trend

Stagnant top‑line growth limits scale benefits and reduces potential for operating‑leverage gains. Over the medium term, flat revenues constrain reinvestment capacity, weaken competitive positioning versus faster‑growing peers and raise execution risk for long‑term targets.

Margin compression and volatile profitability

Sustained margin pressure and swings in net income suggest weaker pricing power or rising costs and inconsistent operational execution. This undermines earnings quality and makes free cash flow and returns on invested capital less predictable over the coming quarters.

Rising debt trend and reduced equity in 2025

An increasing debt burden alongside lower equity reduces financial flexibility and raises leverage risk. Higher indebtedness can increase interest costs and constrain strategic choices (M&A, R&D, pricing support), leaving the company more exposed to demand or margin shocks.

Getinge Business Overview & Revenue Model

Company Description

Getinge (GETI.B) is a global medical technology company that specializes in providing innovative solutions for healthcare and life sciences. The company operates primarily in three sectors: Surgical Workflows, Critical Care, and Life Science. Getinge's core products include surgical tables, operating room integration systems, advanced ventilators, cardiopulmonary products, and solutions for the biopharmaceutical industry, aimed at improving patient outcomes and enhancing operational efficiency in hospitals and laboratories.

How the Company Makes Money

Getinge generates revenue through the sale of medical devices, equipment, and services across its key sectors. The company has established multiple revenue streams, including the direct sale of its products to healthcare facilities, ongoing maintenance and service contracts, and consumables that accompany their devices. Additionally, Getinge benefits from partnerships with hospitals, research institutions, and other healthcare providers, which help to drive sales and foster long-term customer relationships. The company also invests in research and development to innovate and expand its product offerings, further contributing to its earnings through the introduction of new technologies that meet evolving market demands.

Getinge Financial Statement Overview

Summary

Moderate overall fundamentals: reasonable leverage and consistently positive cash generation support stability, but revenue has been fairly flat and profitability/cash flow have been volatile with margin compression versus 2020–2022.

Income Statement

Revenue has been relatively flat over the last two years (2024 modest growth, 2025 slight decline), while profitability has been volatile. Margins have compressed versus earlier years (2020–2022), with net income dropping materially in 2024 before rebounding in 2025. The business still generates solid gross profit dollars, but the trajectory shows weakening pricing/operating leverage and less consistent earnings power than earlier in the period.

Balance Sheet

Leverage remains reasonable with debt levels generally moderate relative to equity (e.g., debt-to-equity around one-third in 2024 and lower in 2022–2023), supporting financial flexibility. However, debt has trended up since 2022 and equity declined in 2025 versus 2024, which is a mild negative. Returns on equity have also stepped down from earlier peaks, indicating reduced efficiency in converting the capital base into profits.

Cash Flow

Cash generation is positive and fairly resilient: operating cash flow and free cash flow remain solid in absolute terms, and free cash flow was strong in 2024 before declining in 2025. Conversion of profits into free cash flow is decent (free cash flow below net income in recent years, but still meaningful). The main weakness is variability—free cash flow growth has swung notably across years, and 2025 shows a clear step-down from 2024 levels.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	34.97B	34.76B	31.83B	28.29B	27.05B
Gross Profit	15.54B	16.15B	14.49B	13.41B	13.58B
EBITDA	5.85B	5.31B	5.93B	5.73B	6.15B
Net Income	2.26B	1.64B	2.41B	2.49B	2.97B
Balance Sheet
Total Assets	56.51B	63.92B	53.59B	52.03B	44.55B
Cash, Cash Equivalents and Short-Term Investments	3.40B	2.96B	2.73B	5.68B	4.08B
Total Debt	11.91B	10.73B	8.08B	5.82B	4.31B
Total Liabilities	27.01B	30.71B	23.18B	21.58B	19.38B
Stockholders Equity	29.43B	33.01B	30.17B	30.04B	24.75B
Cash Flow
Free Cash Flow	2.63B	3.27B	1.60B	2.23B	5.63B
Operating Cash Flow	3.95B	4.58B	2.96B	3.37B	6.56B
Investing Cash Flow	-2.96B	-4.55B	-6.54B	-1.47B	-1.33B
Financing Cash Flow	-765.00M	504.00M	511.00M	-500.00M	-7.24B

Getinge Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 216.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Negative. The current price of 216.9 is above the 20-day moving average (MA) of 213.74, above the 50-day MA of 212.47, and above the 200-day MA of 202.80, indicating a bearish trend. The MACD of -4.59 indicates Positive momentum. The RSI at 27.40 is Positive, neither overbought nor oversold. The STOCH value of 5.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GETI.B.

Getinge Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	71 Outperform	kr15.74B	35.68	3.34%	0.80%	-1.29%	―
CEVI	71 Outperform	kr3.52B	23.22	17.89%	1.61%	1.53%	0.79%
XVIVO	60 Neutral	kr7.09B	281.92	1.32%	―	8.39%	-85.36%
SECT.B	58 Neutral	kr42.97B	65.63	38.97%	0.43%	10.08%	68.12%
GETI.B	57 Neutral	kr53.22B	23.57	6.91%	2.16%	6.74%	21.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEDANA	48 Neutral	kr997.34M	-24.54	-4.42%	―	13.48%	28.98%

Getinge Corporate Events

Getinge Ends 2025 With Record Q4, Strong Organic Growth and Higher Underlying Profitability

Getinge reported a record fourth quarter and full-year 2025 organic sales growth of 4.9%, at the upper end of its guidance, driven by higher demand for ECLS consumables, acute care therapies, transplant care and ventilators, while Surgical Workflows strengthened its leading position in operating tables and entered 2026 with robust order bookings. Despite more than SEK 1 billion in tariff and currency headwinds and a slight decline in adjusted earnings per share and free cash flow versus 2024, the company maintained its full-year adjusted EBITA margin at 14% and achieved significantly higher underlying profitability when excluding these effects, supported by price adjustments, productivity gains and cost control; new product launches such as the Automatiq robotic sterile reprocessing system and regulatory milestones for Rotaflow ECLS consumables and the iCast covered stent further bolstered its competitive position, and management signaled confidence in long-term growth with a proposed higher dividend and an outlook for 3–5% organic sales growth in 2026 despite geopolitical uncertainty.

The most recent analyst rating on ($SE:GETI.B) stock is a Hold with a SEK230.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.

Getinge Schedules Conference Call for 2025 Year-End Report

Getinge will publish its Year-End Report for 2025 on January 27, 2026, and will host a same-day conference call led by President & CEO Mattias Perjos and CFO Agneta Palmér for fund managers, analysts and media. The call, which will be accompanied by a webcast presentation and followed by a three-year-available recording, underscores the company’s efforts to maintain transparency with capital markets and other stakeholders regarding its financial performance and strategic development.

The most recent analyst rating on ($SE:GETI.B) stock is a Hold with a SEK230.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.

Getinge to Strengthen Board with Former Novo Nordisk Executive Camilla Sylvest

Getinge’s Nomination Committee plans to propose seasoned healthcare executive Camilla Sylvest for election to the company’s Board of Directors at the 2026 Annual General Meeting, while long-serving board member Malin Persson has declined re-election after more than a decade of service. Sylvest’s extensive commercial and leadership experience from Novo Nordisk, including oversight of global strategy and major product launches in diabetes, obesity and cardiovascular disease, as well as her current board role at biotechnology group argenx, would strengthen Getinge’s governance with deep expertise in high-growth therapeutic areas and global market development, potentially sharpening the company’s strategic positioning in the competitive medtech and life sciences landscape.

The most recent analyst rating on ($SE:GETI.B) stock is a Hold with a SEK231.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.